Why? Mid-single digit top line growth, double-digit bottom line, with no help from drug pricing, but a growing pipeline of new product launches. Healthcare reform continues to slip to the back burners of the Washington, D.C. agenda as other items take priority. The sector has many great balance sheets with above average dividend yields. As the chart shows, the U.S. pharma multiples are trading at discounts not seen in over a decade.
This material is for informational purposes only, it is not intended to serve as a substitute for personalized investment advice or as a recommendation or solicitation of any particular security, strategy, or investment product. Opinions expressed herein are based on economic and market conditions at the time this material was written, and do not necessarily reflect the views of LVW Advisors. Economies and markets fluctuate. Actual economic or market events may turn out differently than anticipated. Facts presented have been obtained from sources believed to be reliable.
